Research To Practice | Oncology Videos

Latest Episodes:

Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates Sep 01, 2025

Show notes

Featuring an interview with Dr Erika Hamilton, including the following topics:

Monitoring, mitigating and managing adverse events with antibody-drug conjugates (ADCs) for breast cancer (0:00)
- Heist RS et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. Abstract
Management protocols for adverse events associated with sacituzumab govitecan (7:49)
- García JMP et al. Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial. ASCO 2024;Abstract 1101.
- Pérez-García JM et al. Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): An open-label, single-arm, phase 2 trial. eClinicalMedicine 2025;85:103309. Abstract
Datopotamab deruxtecan for patients with breast cancer brain metastases or leptomeningeal disease (10:51)
- Tarantino P et al. DATO-Base: A phase II study of DATOpotamab deruxtecan for patients with breast cancer brain metastases or leptomeningeal disease. ASCO 2025;Abstract TPS1134.
Sequencing ADCs in breast cancer (13:12)
- Pacholczak-Madej R et al. Sequencing of antibody drug conjugates in breast cancer: Evidence gap and future directions. Biochim Biophys Acta Rev Cancer 2025;[Online ahead of print]. Abstract

CME information and select publications

Relapsed/Refractory Multiple Myeloma — Oncology Q&A: Discussing Common Questions Posed by Patients Aug 29, 2025

Show notes

Featuring perspectives from Dr Natalie S Callander and Dr Sagar Lonial, including the following topics:

Introduction (0:00)
A Farmer with Myeloma; Is Myeloma the New Chronic Myeloid Leukemia? (2:06)
Clinical Trials (12:34)
Chimeric Antigen Receptor Therapy (16:11)
Bispecific Antibodies (21:38)
Antibody-Drug Conjugates; a Patient on Belantamab Mafodotin for 3 Years (30:45)
Treatment Options for Relapsed Disease (40:46)
Neuropathy (44:43)
Alternative Therapies (48:36)
164 Questions (53:20)

CME information and select publications

Biliary Tract Cancers — Expert Perspectives on Actual Patient Cases: Part 2 of 2 Aug 28, 2025

Show notes

Featuring perspectives from Dr Haley Ellis and Dr James J Harding, including the following topics:

Introduction: Is Biliary Tract Cancer (BTC) the New Non-Small Cell Lung Cancer? … Why? (0:00)
Case: A woman in her mid 70s with metastatic cholangiocarcinoma receives first-line gemcitabine/cisplatin with durvalumab — Warren S Brenner, MD (8:42)
Case: A man in his late 70s with metastatic biliary cancer (HER2 IHC 2+) discontinues first-line chemotherapy/immunotherapy because of exacerbation of Crohn's disease — Neil Morganstein, MD (17:48)
Case: A man in his early 70s with metastatic cholangiocarcinoma (FGFR2 rearrangement) receives gemcitabine/oxaliplatin with durvalumab and experiences a rapid clinical decline — Kimberly Ku, MD (27:14)
Case: A woman in her late 40s with Stage IV recurrent cholangiocarcinoma (FGFR2 rearrangement) receives pemigatinib — Justin Peter Favaro, MD, PhD (40:15)
Case: A woman in her early 60s with HER2-positive cholangiocarcinoma develops metastatic disease during adjuvant capecitabine therapy — Dr Morganstein (46:09)

CME information and select publications

Brain Metastases with HER2-Positive Breast Cancer — An Interview with Dr Sarah Sammons on Optimal Management Approaches Aug 26, 2025

Show notes

Featuring an interview with Dr Sarah Sammons, including the following topics:

Development of brain metastases in patients with HER2-positive and HER2-negative breast cancer (0:00)
Local therapy approaches for the treatment of brain metastases (8:23)
Treatment options for patients with HER2-positive breast cancer and CNS-only disease progression (16:36)
Clinical presentation of leptomeningeal disease; management of functional sequelae associated with brain metastases (19:07)
Investigational agents for the treatment of brain metastases in HER2-positive breast cancer (25:01)
Case: A 65-year-old woman with ER-negative, HER2-positive metastatic breast cancer (mBC) develops a single 6-mm brain metastasis after 4 years of maintenance trastuzumab/pertuzumab (27:38)
Screening for brain metastases; radiation necrosis as a side effect of radiation therapy (31:00)
Case: A 39-year-old woman with ER-negative, HER2-positive mBC develops 7 new brain metastases 6 months into treatment with a taxane, trastuzumab and pertuzumab (34:30)

CME information and select publications

Brain Metastases with HER2-Positive Breast Cancer — An Interview with Dr Sarah Sammons on Optimal Management Approaches (Companion Faculty Lecture) Aug 25, 2025

Show notes

Featuring a slide presentation and related discussion from Dr Sarah Sammons.

CME information and select publications

Small Cell Lung Cancer — Expert Perspectives on Actual Patient Cases Aug 22, 2025

Show notes

Featuring perspectives from Dr Stephen V Liu and Dr Charles Rudin, including the following topics:

Introduction (0:00)
Case 1: Adjuvant Systemic Therapy? (1:15)
Case 2: Lambert-Eaton Syndrome and Other Paraneoplastic Syndromes (4:16)
Case 3: Small Cell Transformation of EGFR-Mutant Non-Small Cell Lung Cancer (9:54)
Case 4: Trilaciclib in Extensive-Stage Disease (13:50)
Comments: ASCO and Other Recent Datasets (18:05)
Case 5: Short Disease-Free-Interval with Brain Metastases After Chemoradiation Therapy/Durvalumab … Lurbinectedin? (39:34)
Case 6: Tarlatamab After Rapid Disease Progression on Chemotherapy/Atezolizumab (44:33)
Case 7: Immune Effector Cell-Associated Neurotoxicity Syndrome on Tarlatamab with Brain Metastases (48:54)
Case 8: Bispecific T-Cell Engager with Lurbinectedin on Protocol (56:38)

CME information and select publications

Ovarian and Endometrial Cancer — An Interview with Dr Shannon Westin on the Current Management Paradigm Aug 20, 2025

Show notes

Featuring an interview with Dr Shannon N Westin, including the following topics:

Biomarker testing and utility in ovarian cancer (OC) (0:00)
Selection of a PARP inhibitor for the treatment of OC (9:18)
Addition of immunotherapy to up-front treatment of OC (15:50)
Utility of minimal residual disease and circulating tumor DNA assays in OC (17:10)
Selection of treatment for recurrent OC (21:46)
Clinical decision-making involved with PARP inhibitors for endometrial cancer (EC) (28:22)
Adjuvant therapy for EC (32:28)
Utility of lenvatinib/pembrolizumab in EC (35:08)
Clinical findings supporting the potential use of selinexor for EC (39:42)
Key findings involving trastuzumab deruxtecan (T-DXd) for HER2-positive gynecologic cancers (43:22)
Management of adverse effects associated with T-DXd (49:49)

CME information and select publications

Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 1 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates Aug 15, 2025

Show notes

Featuring an interview with Dr Jacob Sands, including the following topics:

TROPION-Lung05 Trial: Datopotamab Deruxtecan for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations (0:00)
- Sands J et al. Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: Results from the phase II TROPION-Lung05 study. J Clin Oncol 2025;43(10):1254-65. Abstract
Phase III Randomized Clinical Trial Data with TROP2-Targeting Antibody-Drug Conjugates for Previously Treated Advanced NSCLC (6:52)
- Ahn M-J et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: The randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol 2025;43(3):260-72. Abstract
- Reinmuth N et al. Longer follow-up for survival and safety from the EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel in patients (pts) with metastatic non-small cell lung cancer (mNSCLC). ASCO 2025;Abstract 8599.
- Paz-Ares LG et al. Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1 inhibitors (IO): Primary results from the phase 3 EVOKE-01 study. ASCO 2024;Abstract LBA8500.
Evaluating TROP2 Expression Levels Through Normalized Membrane Ratio of TROP2 in the TROPION-Lung01 Trial (12:26)
- Garassino MC et al. Normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-Lung01. WCLC 2024;Abstract PL02.11.

CME information and select publications

Multiple Myeloma | Oncology Q&A for Patients: Clinical Experts Address Common Questions Posed by Patients with Relapsed/Refractory Multiple Myeloma Aug 15, 2025

Show notes

Featuring perspectives from Dr Natalie S Callander and Dr Sagar Lonial, including the following topics:

Introduction: Multiple Myeloma — 2005 to 2025 (0:00)
Questions from the Beginning (7:53)
Choosing Options (13:54)
Clinical Trials (18:03)
Neuropathy (23:55)
Chimeric Antigen Receptor (CAR) T-Cell Therapy (28:40)
Bispecific Antibodies (35:18)
Antibody-Drug Conjugates (43:08)
Interacting with the Oncology Team (51:47)
Other Questions (57:30)

Educational and presenter information

Acute Myeloid Leukemia — An Interview with Dr Jorge Cortes on Optimal Management of FLT3 and IDH1/2 Mutations Aug 12, 2025

Show notes

Featuring an interview with Dr Jorge Cortes, including the following topics:

Overview of common molecular profiles in newly diagnosed acute myeloid leukemia (AML) (0:00)
Clinical presentation of AML with a FLT3 mutation; implications of clinical data from the Phase III RATIFY trial of the FLT3 inhibitor midostaurin (5:38)
Potential incorporation of a FLT3 inhibitor with azacitidine/venetoclax for transplant-ineligible patients with FLT3-mutant AML (10:32)
Clinical benefit with quizartinib for patients with FLT3-like genetic profile; selection of FLT3 inhibitor as a component of initial therapy for individuals with AML with a FLT3-ITD mutation (14:04)
Overview of FDA-approved IDH inhibitors enasidenib, ivosidenib and olutasidenib; differentiation syndrome as a class effect of IDH inhibitors in AML (20:31)
Case: A woman in her late 60s with newly diagnosed AML with FLT3-ITD and NPM1 mutations receives 7+3 chemotherapy in combination with quizartinib (31:07)
Case: A patient in their late 70s with multiple comorbidities and newly diagnosed IDH1-mutant AML (37:53)

CME information and select publications